Glioma cells produce soluble PD-L1 via the Wnt/β-catenin signaling pathway to suppress CD8+ T cell activity.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: high Ki-67 expression, IDH-wild type or high-grade have higher level of sPD-L1
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We conclude that glioma cells produce sPD-L1 through the Wnt/β-catenin signaling pathway, which interacts with the PD-1 receptor on CD8 T cells, inhibiting their function by reducing IFN-γ levels. Wnt inhibitors combined with PD-L1 inhibitors can enhance the anti-tumor effect by further reducing sPD-L1 levels.
Soluble programmed death ligand 1 (sPD-L1) is emerging as a novel prognostic marker, potentially replacing PD-L1 for assessing prognosis and immunotherapy effectiveness.
APA
Zhou Z, Wang Y, et al. (2025). Glioma cells produce soluble PD-L1 via the Wnt/β-catenin signaling pathway to suppress CD8+ T cell activity.. Biochimica et biophysica acta. Molecular basis of disease, 1871(8), 168013. https://doi.org/10.1016/j.bbadis.2025.168013
MLA
Zhou Z, et al.. "Glioma cells produce soluble PD-L1 via the Wnt/β-catenin signaling pathway to suppress CD8+ T cell activity.." Biochimica et biophysica acta. Molecular basis of disease, vol. 1871, no. 8, 2025, pp. 168013.
PMID
40784599 ↗
Abstract 한글 요약
Soluble programmed death ligand 1 (sPD-L1) is emerging as a novel prognostic marker, potentially replacing PD-L1 for assessing prognosis and immunotherapy effectiveness. However, little is known about sPD-L1. This study aimed to assess sPD-L1's potential as a biomarker and explore its origin and biological function. The study found sPD-L1 concentration in plasma is linked to worse overall survival (OS) in glioma. Patients with high Ki-67 expression, IDH-wild type or high-grade have higher level of sPD-L1. Notably, sPD-L1 concentration is positive correlations with tumor volume in patients and mice. Mice plasma with varying sPD-L1 concentration was co-cultured with CD8 T cells to investigate sPD-L1 activity and function. We conclude that glioma cells produce sPD-L1 through the Wnt/β-catenin signaling pathway, which interacts with the PD-1 receptor on CD8 T cells, inhibiting their function by reducing IFN-γ levels. Wnt inhibitors combined with PD-L1 inhibitors can enhance the anti-tumor effect by further reducing sPD-L1 levels.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Post-Translational Regulation of CD8 T Cell Fate and Dysfunction in Tumor Immunity.
- Shiny-MAGEC: A Bayesian R shiny application for meta-analysis of censored adverse events.
- Long-term survival in a case report with metachronous quadruple primary malignancies involving multiple organ systems.
- Extracellular matrix stiffness in hepatocellular carcinoma: mechanisms and targeted therapeutic strategies.
- Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SpNeigh: spatial neighborhood and differential expression analysis for high-resolution spatial transcriptomics.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The tumor microenvironment as a key regulator of radiotherapy response.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Advances in green-synthesized magnetic nanoparticles for targeted cancer therapy: mechanisms, applications, and future perspectives.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.